Filtered By:
Specialty: General Medicine
Drug: Pradaxa
Management: Health Insurance
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Or ális antikoagulánssal kezelt pitvarfibrilláló betegek terápiahűsége a mindennapokban.
Conclusions: The one-year persistence of NOACs was significantly higher in AF compared to VKA therapy (in therapy-naïve and in already treated patients, too). Among the NOACs, rivaroxaban has the best one-year persistence in all patient populations. Orv Hetil. 2020; 161(20): 839-845.
PMID: 32364687 [PubMed - in process]
Source: Orvosi Hetilap - April 30, 2020 Category: General Medicine Authors: Simonyi G, Paksy A, Várnai R, Medvegy M Tags: Orv Hetil Source Type: research
